Home
Eirik Bratland's picture

Eirik Bratland

Researcher
  • E-maileirik.bratland@uib.no
  • Phone+47 55 97 58 46
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2024). Improving diagnostic precision in primary ovarian insufficiency using comprehensive genetic and autoantibody testing. Human Reproduction. 177-189.
  • Show author(s) (2023). MSMO1 deficiency: a potentially partially treatable, ultrarare neurodevelopmental disorder with psoriasiform dermatitis, alopecia and polydactyly. Clinical Dysmorphology. 97-105.
  • Show author(s) (2023). A partial form of AIRE deficiency underlies a mild form of autoimmune polyendocrine syndrome type 1. Journal of Clinical Investigation.
  • Show author(s) (2022). Screening patients with autoimmune endocrine disorders for cytokine autoantibodies reveals monogenic immune deficiencies. Journal of Autoimmunity. 1-?.
  • Show author(s) (2021). Truncating and zinc-finger variants in GLI2 are associated with hypopituitarism. American Journal of Medical Genetics. Part A. 1-10.
  • Show author(s) (2021). Transcriptional changes in regulatory T cells from patients with autoimmune polyendocrine syndrome type 1 suggest functional impairment of lipid metabolism and gut homing. Frontiers in Immunology. 1-12.
  • Show author(s) (2021). The natural history of 21-hydroxylase autoantibodies in autoimmune Addison’s disease. European Journal of Endocrinology (EJE). 607-615.
  • Show author(s) (2021). The SH3PXD2A-HTRA1 fusion transcript is extremely rare in Norwegian sporadic vestibular schwannoma patients. Journal of Neuro-Oncology. 35-40.
  • Show author(s) (2021). Potential Transcriptional Biomarkers to Guide Glucocorticoid Replacement in Autoimmune Addison's Disease. Journal of the Endocrine Society (JES). 1-10.
  • Show author(s) (2021). Mechanistic dissection of dominant AIRE mutations in mouse models reveals AIRE autoregulation. Journal of Experimental Medicine (JEM).
  • Show author(s) (2021). GWAS for autoimmune Addison's disease identifies multiple risk loci and highlights AIRE in disease susceptibility. Nature Communications. 1-14.
  • Show author(s) (2021). Bi-allelic KARS1 pathogenic variants affecting functions of cytosolic and mitochondrial isoforms are associated with a progressive and multisystem disease. Human Mutation. 745-761.
  • Show author(s) (2021). 21-Hydroxylase-Specific CD8+ T Cells in Autoimmune Addison’s Disease Are Restricted by HLA-A2 and HLA-C7 Molecules. Frontiers in Immunology. 12 pages.
  • Show author(s) (2020). Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study. Immunity,Inflammation and Disease. 342-359.
  • Show author(s) (2019). Identification and characterization of rare Toll-like receptor 3 variants in patients with autoimmune Addison’s disease. Journal of translational autoimmunity.
  • Show author(s) (2019). Coexistence of congenital adrenal hyperplasia and autoimmune Addison's disease. Frontiers in Endocrinology. 1-5.
  • Show author(s) (2018). The potential role for infections in the pathogenesis of autoimmune Addison?s disease. Clinical and Experimental Immunology. 1-12.
  • Show author(s) (2018). Longitudinal cohort study of serum antibody responses towards Giardia lamblia variant-specific surface proteins in a non-endemic area. Experimental parasitology. 66-72.
  • Show author(s) (2018). Autoimmune Addison's disease – An update on pathogenesis. Annales d'Endocrinologie. 157-163.
  • Show author(s) (2017). Increased infiltration and tolerised antigen-specific CD8+ TEM cells in tumor but not peripheral blood have no impact on survival of HCMV+ glioblastoma patients. Oncoimmunology. 1-15.
  • Show author(s) (2017). Altered immune activation and IL-23 signaling in response to Candida albicans in autoimmune polyendocrine syndrome type 1. Frontiers in Immunology. 1-10.
  • Show author(s) (2016). Anticommensal responses are associated with regulatory T cell defect in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients. Journal of Immunology. 2955-2964.
  • Show author(s) (2016). Analysis of cellular and humoral immune responses against cytomegalovirus in patients with autoimmune Addison's disease. Journal of Translational Medicine.
  • Show author(s) (2016). A longitudinal follow-up of autoimmune polyendocrine syndrome type 1. Journal of Clinical Endocrinology and Metabolism (JCEM). 2975-2983.
  • Show author(s) (2015). Peripheral blood cells from patients with autoimmune Addison's disease poorly respond to interferons in vitro, despite elevated serum levels of interferon-inducible chemokines. Journal of Interferon and Cytokine Research. 759-770.
  • Show author(s) (2015). Interleukin-2 and subunit alpha of its soluble receptor in autoimmune Addison's disease - An association study and expression analysis. Autoimmunity. 100-107.
  • Show author(s) (2015). Hypomagnesemia and functional hypoparathyroidism due to novel mutations in the Mg-channel TRPM6. Endocrine Connections. 215-222.
  • Show author(s) (2015). Dominant mutations in the autoimmune regulator AIRE are associated with common organ-specific autoimmune diseases. Immunity. 1185-1196.
  • Show author(s) (2014). The effect of types I and III interferons on adrenocortical cells and its possible implications for autoimmune Addison's disease. Clinical and Experimental Immunology. 351-362.
  • Show author(s) (2014). High frequency of cytolytic 21-hydroxylase-specific CD8+ T cells in autoimmune Addison's disease patients. Journal of Immunology. 2118-2126.
  • Show author(s) (2014). Functional studies of novel CYP21A2 mutations detected in Norwegian patients with congenital adrenal hyperplasia. Endocrine Connections. 67-74.
  • Show author(s) (2014). CYP21A2 polymorphisms in patients with autoimmune Addison's disease, and linkage disequilibrium to HLA risk alleles. European Journal of Endocrinology (EJE). 743-750.
  • Show author(s) (2014). Altered DNA methylation profile in Norwegian patients with Autoimmune Addison's Disease. Molecular Immunology. 208-216.
  • Show author(s) (2014). A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with autoimmune polyendocrine syndrome type 1. Clinical Immunology. 220-227.
  • Show author(s) (2013). Induction of CXCL10 chemokine in adrenocortical cells by stimulation through toll-like receptor 3. Molecular and Cellular Endocrinology. 75-83.
  • Show author(s) (2013). Autoantibodies against aromatic amino acid hydroxylases in patients with autoimmune polyendocrine syndrome type 1 target multiple antigenic determinants and reveal regulatory regions crucial for enzymatic activity. Immunobiology. 899-909.
  • Show author(s) (2011). Cellular immunity and immunopathology in autoimmune Addison’s disease. Molecular and Cellular Endocrinology. 180-190.
  • Show author(s) (2009). The purification and application of biologically active recombinant steroid cytochrome P450 21-hydroxylase: The major autoantigen in autoimmune Addison's disease. Journal of Autoimmunity. 58-67.
  • Show author(s) (2009). T Cell Responses to Steroid Cytochrome P450 21-Hydroxylase in Patients with Autoimmune Primary Adrenal Insufficiency. Journal of Clinical Endocrinology and Metabolism (JCEM). 5117-5124.
  • Show author(s) (2008). Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I. Clinical Immunology. 163-169.
  • Show author(s) (2007). Epitope mapping of human aromatic L-amino acid decarboxylase. Biochemical and Biophysical Research Communications - BBRC. 692-698.
  • Show author(s) (2006). The substrate-binding domain of 21-hydroxylase, the main autoantigen in autoimmune Addison's disease, is an immunodominant T cell epitope. Endocrinology. 2411-2416.
Doctoral dissertation
  • Show author(s) (2016). Immuno-endocrine interactions in autoimmune Addison's disease.
  • Show author(s) (2015). Autoimmunity and viral immunity in Addison’s disease.
  • Show author(s) (2009). Cellular immunity in autoimmune Addison's disease : T cell responses to steroid cytochrome P450 21-hydroxylase.
Abstract
  • Show author(s) (2013). Characterisation of the CYP21A2 Gene in Patients with Autoimmune Addison's Disease. Scandinavian Journal of Immunology. 310-310.
  • Show author(s) (2012). Poly (I:C)-induced CXCL10 production in adrenocortical cells - implications for autoimmune Addison's disease? Immunology. 300-301.
  • Show author(s) (2012). Mice deficient for the autoimmune regulator, Aire, display altered T cell responses against 21-hydroxylase, the major autoantigen in autoimmune Addison's disease. Immunology. 542-542.
  • Show author(s) (2012). Increased antibody levels against gut commensals are associated with regulatory T cell defect in patients with APECED. Immunology. 421-421.
  • Show author(s) (2011). Endogenous Production of CXC Chemokine Ligand 10 (CXCL10) by Adrenocortical Cells and its Implications for Autoimmune Addison's Disease. Scandinavian Journal of Immunology. 371-371.
  • Show author(s) (2010). The Possible Roles of Interferon-Gamma, CXC Chemokine Ligand 10 (CXCL10) and the CXCR3 Circuit in the Pathogenesis of Autoimmune Addison's Disease. Scandinavian Journal of Immunology. 479-480.
  • Show author(s) (2008). 21-hydroxylase as a T cell autoantigen in autoimmune Addison's disease. Scandinavian Journal of Immunology. 191-191.
  • Show author(s) (2007). Epitope mapping of human aromatic L-amino acid decarboxylase. Scandinavian Journal of Immunology. 592-592.
Poster
  • Show author(s) (2013). A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with APS-1.

More information in national current research information system (CRIStin)